Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALHCNASDAQ:CLOVNASDAQ:ETNBNASDAQ:MNKD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALHCAlignment Healthcare$15.30+2.7%$17.03$7.05▼$21.06$3.03B1.321.96 million shs1.17 million shsCLOVClover Health Investments$3.13-0.2%$3.49$0.90▼$4.87$1.60B1.996.68 million shs1.97 million shsETNB89bio$9.77-0.5%$7.38$4.16▼$11.84$1.43B1.232.23 million shs329,690 shsMNKDMannKind$4.17+1.1%$4.66$4.05▼$7.63$1.27B1.142.37 million shs674,465 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALHCAlignment Healthcare-1.00%+2.83%-14.52%-5.04%+113.47%CLOVClover Health Investments0.00%-4.57%-9.28%-21.16%+203.88%ETNB89bio+6.28%+1.66%+29.93%+6.28%+22.32%MNKDMannKind+1.23%-2.37%-16.09%-22.85%-9.05%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALHCAlignment Healthcare3.1535 of 5 stars3.34.00.00.03.52.50.6CLOVClover Health Investments2.8556 of 5 stars3.33.00.00.03.22.50.6ETNB89bio2.4048 of 5 stars3.53.00.00.02.70.80.6MNKDMannKind3.0737 of 5 stars3.61.00.00.03.51.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALHCAlignment Healthcare 2.55Moderate Buy$17.1712.20% UpsideCLOVClover Health Investments 2.67Moderate Buy$4.8354.67% UpsideETNB89bio 3.00Buy$26.43170.65% UpsideMNKDMannKind 3.25Buy$10.00140.10% UpsideCurrent Analyst Ratings BreakdownLatest ALHC, CLOV, MNKD, and ETNB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/24/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)5/10/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)5/2/2025ALHCAlignment HealthcareUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$16.00 ➝ $17.004/30/2025ETNB89bioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/24/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)4/15/2025ALHCAlignment HealthcareRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$17.00 ➝ $22.004/10/2025MNKDMannKindMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$12.004/9/2025MNKDMannKindMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/8/2025ALHCAlignment HealthcareStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $23.004/8/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)3/22/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALHCAlignment Healthcare$3.00B1.01N/AN/A$0.84 per share18.21CLOVClover Health Investments$1.49B1.07N/AN/A$0.59 per share5.30ETNB89bioN/AN/AN/AN/A$5.75 per shareN/AMNKDMannKind$297.60M4.25N/AN/A($0.91) per share-4.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALHCAlignment Healthcare-$148.02M-$0.48N/AN/AN/A-5.84%-108.69%-21.89%8/7/2025 (Estimated)CLOVClover Health Investments-$213.36M-$0.05N/AN/AN/A-5.92%-25.46%-12.35%8/4/2025 (Estimated)ETNB89bio-$142.19M-$3.38N/AN/AN/AN/A-59.58%-52.21%8/4/2025 (Estimated)MNKDMannKind-$11.94M$0.1059.5018.11N/A8.07%-17.74%8.68%8/6/2025 (Estimated)Latest ALHC, CLOV, MNKD, and ETNB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025MNKDMannKind$0.03$0.04+$0.01$0.04$75.86 million$78.35 million5/6/2025Q1 2025CLOVClover Health Investments-$0.07$0.05+$0.12N/A$466.93 million$462.33 million5/1/2025Q1 2025ALHCAlignment Healthcare-$0.12-$0.05+$0.07-$0.05$889.83 million$926.93 million5/1/2025Q1 2025ETNB89bio-$0.50-$0.49+$0.01-$0.49N/AN/A3/6/2025Q4 2024ETNB89bio-$0.60-$1.02-$0.42-$1.02N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALHCAlignment HealthcareN/AN/AN/AN/AN/ACLOVClover Health InvestmentsN/AN/AN/AN/AN/AETNB89bioN/AN/AN/AN/AN/AMNKDMannKindN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALHCAlignment Healthcare1.821.601.60CLOVClover Health InvestmentsN/A1.551.55ETNB89bio0.0911.6611.66MNKDMannKindN/A4.544.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALHCAlignment Healthcare86.19%CLOVClover Health Investments19.77%ETNB89bioN/AMNKDMannKind49.55%Insider OwnershipCompanyInsider OwnershipALHCAlignment Healthcare7.00%CLOVClover Health Investments22.28%ETNB89bio2.60%MNKDMannKind3.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALHCAlignment Healthcare850197.84 million179.04 millionOptionableCLOVClover Health Investments680508.92 million389.46 millionOptionableETNB89bio40145.98 million103.15 millionOptionableMNKDMannKind400303.93 million267.51 millionOptionableALHC, CLOV, MNKD, and ETNB HeadlinesRecent News About These CompaniesMannKind Co. (NASDAQ:MNKD) Given Average Recommendation of "Buy" by AnalystsMay 30 at 1:29 AM | americanbankingnews.comINDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29May 27 at 9:15 AM | globenewswire.comVoloridge Investment Management LLC Has $6.86 Million Stake in MannKind Co. (NASDAQ:MNKD)May 27 at 4:39 AM | marketbeat.comNuveen Asset Management LLC Lowers Stake in MannKind Co. (NASDAQ:MNKD)May 27 at 3:53 AM | marketbeat.comMannKind: Why I'm Still Bullish Despite Tyvaso DPI CompetitionMay 27 at 12:42 AM | seekingalpha.comMannKind (NASDAQ:MNKD) versus Edesa Biotech (NASDAQ:EDSA) Head to Head ContrastMay 26, 2025 | americanbankingnews.comTwo Sigma Advisers LP Boosts Stock Holdings in MannKind Co. (NASDAQ:MNKD)May 24, 2025 | marketbeat.comTwo Sigma Investments LP Boosts Stock Holdings in MannKind Co. (NASDAQ:MNKD)May 24, 2025 | marketbeat.comMan Group plc Purchases 219,891 Shares of MannKind Co. (NASDAQ:MNKD)May 24, 2025 | marketbeat.comMillennium Management LLC Has $22.17 Million Stake in MannKind Co. (NASDAQ:MNKD)May 23, 2025 | marketbeat.comMannKind Co. (NASDAQ:MNKD) Shares Acquired by Deutsche Bank AGMay 23, 2025 | marketbeat.comBank of America Corp DE Raises Position in MannKind Co. (NASDAQ:MNKD)May 22, 2025 | marketbeat.comInsider Selling: MannKind Co. (NASDAQ:MNKD) EVP Sells 2,345 Shares of StockMay 21, 2025 | insidertrades.comNomura Holdings Inc. Sells 2,792,237 Shares of MannKind Co. (NASDAQ:MNKD)May 21, 2025 | marketbeat.comMannKind Stockholders Approve Board and CompensationMay 19, 2025 | tipranks.comDavid Thomson Sells 32,179 Shares of MannKind Co. (NASDAQ:MNKD) StockMay 16, 2025 | insidertrades.comMannKind Co. (NASDAQ:MNKD) Stake Lowered by Parkman Healthcare Partners LLCMay 16, 2025 | marketbeat.comCantor Fitzgerald Expects Stronger Earnings for MannKindMay 16, 2025 | marketbeat.comBNP Paribas Financial Markets Boosts Stock Position in MannKind Co. (NASDAQ:MNKD)May 16, 2025 | marketbeat.comMannKind Co. (NASDAQ:MNKD) Shares Purchased by Northern Trust CorpMay 16, 2025 | marketbeat.comMannKind corp director Steven Binder sells $375,875 in stockMay 15, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALHC, CLOV, MNKD, and ETNB Company DescriptionsAlignment Healthcare NASDAQ:ALHC$15.30 +0.40 (+2.68%) As of 12:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Alignment Healthcare, Inc., a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.Clover Health Investments NASDAQ:CLOV$3.12 -0.01 (-0.16%) As of 12:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat. Clover Health Investments, Corp. is based in Franklin, Tennessee.89bio NASDAQ:ETNB$9.76 -0.05 (-0.46%) As of 12:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.MannKind NASDAQ:MNKD$4.16 +0.05 (+1.09%) As of 12:01 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Apple Stock Could Rally After Tariffs Are Blocked By Court Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
